AzTrials
AzTrials

Current Every Day SmokerNCT02224391

Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking

A study testing Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis and Nicotine Patch in people with Current Every Day Smoker, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized clinical trial studies how well a smartphone-delivered attentional bias modification training works in helping patients quit smoking. Smartphone-delivered attentional bias modification training may help patients quit smoking by reducing the attentional bias (the tendency of one's perception to be… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Current Every Day Smoker
What is being tested?
Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis and Nicotine Patch
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
311 participants
Where
1 siteUnited States
Study dates
20 Jan 2016to 15 Mar 2021
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Smoke an average of 5 or more cigarettes or little cigars per day (CPD) prior to telephone screen
  • Produce an expired carbon monoxide (CO) level greater than or equal to 6 parts per million (ppm) or a NicAlert reading of > 2
  • Have a working telephone
  • Interested in quitting smoking in the next 30 days
  • Fluency in spoken and written English
  • Must sign the picture consent form

Who cannot join

  • Taking psychotropic, anticonvulsive, or narcotic medication
  • Meet criteria for a current major depressive episode or suicidality
  • Have a history of neurological illness or closed head injury
  • Report uncorrected vision problems
  • Involved in current smoking cessation activity
  • Testing positive on a urine drug screen for drugs of abuse/potential abuse
Show all 12Show fewer
  • Women who are pregnant or breastfeeding
  • Considered by the investigator to be an unsuitable or unstable candidate (e.g., due to cognitive impairment)
  • Shares the same address as a currently enrolled participant
  • Unwilling to alter or remove hairstyle, hair extensions, or wig during the clinic visits to allow for correct electroencephalography (EEG) sensor placement
  • Reports diagnosis of seizure disorder
  • Unwilling to use nicotine replacement therapy (NRT) patches

Trial locations and contacts

1 site in 1 country.

United States1 site
  • M D Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Smartphone-Delivered Attentional Bias Modification Training for Quitting Smokers

This randomized clinical trial studies how well a smartphone-delivered attentional bias modification training works in helping patients quit smoking. Smartphone-delivered attentional bias modification training may help patients quit smoking by reducing the attentional bias (the tendency of one's perception to be affected by their recurring thoughts) towards smoking cues that developed over time as a result of conditioning processes through which smoking cues become important.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To determine the feasibility of smartphone-delivered, in-home attentional bias modification (ABM) to reduce attentional bias (AB) to smoking cues and to reduce smoking behavior in the short- and long-term.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.

ARM II: Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.

After completion of study treatment, patients are followed up on days 15, 29, 43, 57, and 72.

Being tested
Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Sham Intervention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Computer-Assisted Smoking Cessation InterventionBehavioural

    Receive ABM training via a smartphone

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Nicotine PatchDrug

    Also called NicoDerm CQ, Nicotine Skin Patch, Nicotine Transdermal Patch

    Given via transdermal patch

  • Questionnaire AdministrationOther

    Ancillary studies

  • Sham InterventionOther

    Undergo sham training

Study groups in NCT02224391
Study groupRoleWhat they receive
Arm I (ABM training)ExperimentalPatients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
Receives: Behavioral: Computer-Assisted Smoking Cessation Intervention; Other: Laboratory Biomarker Analysis; Drug: Nicotine Patch; Other: Questionnaire Administration
Arm II (sham training)Sham comparatorPatients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
Receives: Other: Laboratory Biomarker Analysis; Drug: Nicotine Patch; Other: Questionnaire Administration; Other: Sham Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Modified Dot-probe Task

    Modified dot-probe task evaluated by using 2 (group: ABM vs. sham) X 3 (session: baseline, 1-day post-training, and 8-weeks post-training) linear mixed model using RT difference scores (neutral-cigarette) as the dependent measures and subject as the random effect.

    Measured: Up to 8 weeks post-training

  2. Smoking Stroop Task

    The Stroop task will consist of three blocks, with a 5-s rest period between blocks: (a) practice (40 trials), (b) neutral words (80 trials), and (c) smoking words (80 trials). The score will be calculated by taking the mean RT difference between the smoking and neutral words on trials with correct responses within the response window.

    Measured: Up to 8 weeks post-training

Secondary outcomes (5)
  1. Cigarette Per Day (CPD)

    Mean number of cigarettes per day smoked for the seven days preceding each time point.

    Measured: Up to 8 weeks post-training

  2. Expired Carbon Monoxide (CO)

    Mean expired carbon monoxide, in ppm (parts per million), at each time point.

    Measured: Up to 8 weeks post-training

  3. Urinary Cotinine

    Mean urinary cotinine, measured in ng/mL, at each time point.

    Measured: Up to 8 weeks post-training

  4. Fagerström Test for Nicotine Dependence (FTND)

    The Fagerström Test for Nicotine Dependence, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine. Mean Fagerström Test for Nicotine Dependence (FTND) questionnaire score at each time point.

    Measured: Up to 8 weeks post-training

  5. Wisconsin Smoking Withdrawal Scale (WSWS) - Craving

    Mean Wisconsin Smoking Withdrawal Scale (WSWS) - Craving subscale score at each time point. Participants rate each item on a scale of 0-4 (0=Strongly disagree, 1=Disagree, 2=Feel neutral, 3=Agree, 4=Strongly agree). The subscale to each item is determined on how high they agree on the scale. Mean Wisconsin Smoking Withdrawal Scale (WSWS) - Craving subscale score at each time point. For some items, the subscale is determined on how low they agreed. Each score is determined by the mean of each item that applies. Higher means indicate greater withdrawal.

    Measured: Up to 8 weeks post-training

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2014 (estimated)
  2. Study start20 Jan 2016
  3. Primary completion15 Mar 2021
  4. Study completion15 Mar 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
311 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02224391
Sponsor's protocol ID
2013-0999
Other IDs
NCI-2015-00609, 2013-0999
Status last verified
Mar 2023
First submitted
21 Aug 2014
Last updated
7 Mar 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Robinson JD, Cui Y, Engelmann JM, Kypriotakis G, Cinciripini PM. Using eye tracking to evaluate the impact of smartphone-delivered attentional bias modification training for smokers. Exp Clin Psychopharmacol. 2024 Dec;32(6):728-736. doi: 10.1037/pha0000729. Epub 2024 Jun 27.

    PubMed 38934914
  • Robinson JD, Cui Y, Linares Abrego P, Engelmann JM, Prokhorov AV, Vidrine DJ, Shete S, Cinciripini PM. Sustained reduction of attentional bias to smoking cues by smartphone-delivered attentional bias modification training for smokers. Psychol Addict Behav. 2022 Nov;36(7):906-919. doi: 10.1037/adb0000805. Epub 2022 Jan 13.

    PubMed 35025555

Questions about this trial

What is this clinical trial studying?

A study testing Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis and Nicotine Patch in people with Current Every Day Smoker, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Modified Dot-probe Task (time frame: Up to 8 weeks post-training). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02224391, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in